Ketoconazole-associated preferential increase in dopamine D2 receptor occupancy in striatum compared to pituitary in vivo: role for drug transporters?
- PMID: 22198458
- DOI: 10.1097/JCP.0b013e3182408fc8
Ketoconazole-associated preferential increase in dopamine D2 receptor occupancy in striatum compared to pituitary in vivo: role for drug transporters?
Abstract
Membrane transporters such as P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) are efflux pumps that remove drugs from the brain back to the peripheral blood compartment, serving as a functional component of the blood-brain barrier (BBB). We report here that coadministration of the P-gp and BCRP inhibitor ketoconazole with risperidone may preferentially increase D2 receptor occupancy in the striatum compared to pituitary. Four male patients with schizophrenia or schizoaffective disorder who had received at least 4 prior injections of the long-acting risperidone at a stable dose of 25 to 50 mg participated in this positron emission tomography study. Multiple-dose ketoconazole coadministration reduced the P-gp activity as shown by fexofenadine oral challenge. Importantly, we found a strong statistical trend in this sample of 4 subjects who consistently showed a decrease in striatal fluorine 18 (F)-fallypride binding (an indication of increased D2 receptor occupancy) after ketoconazole coadministration (P = 0.057), whereas the pituitary (a region that lies outside the BBB) F-fallypride binding did not change (P = 0.99). These observations warrant further research with selective drug transporter inhibitors. We suggest that in neuroimaging studies, the pituitary drug occupancy can serve as a useful new "positive control" to evaluate whether drug occupancy is preferentially increased in brain regions that fall inside the BBB after cotreatment with P-gp and BCRP inhibitors. This is a noteworthy study design consideration regarding the future clinical testing of novel adjunct interventions aimed at modulating membrane transporter function at the BBB, with the goal of augmenting drug access into the brain compartment, particularly in treatment-resistant psychiatric illness.
Similar articles
-
Positron emission tomography measurement of dopamine D₂ receptor occupancy in the pituitary and cerebral cortex: relation to antipsychotic-induced hyperprolactinemia.J Clin Psychiatry. 2010 Sep;71(9):1131-7. doi: 10.4088/JCP.08m04307yel. Epub 2010 Feb 23. J Clin Psychiatry. 2010. PMID: 20361897
-
A PET study evaluating dopamine D2 receptor occupancy for long-acting injectable risperidone.Am J Psychiatry. 2006 Mar;163(3):396-401. doi: 10.1176/appi.ajp.163.3.396. Am J Psychiatry. 2006. PMID: 16513859
-
Dose-occupancy study of striatal and extrastriatal dopamine D2 receptors by aripiprazole in schizophrenia with PET and [18F]fallypride.Neuropsychopharmacology. 2008 Dec;33(13):3111-25. doi: 10.1038/npp.2008.33. Epub 2008 Apr 16. Neuropsychopharmacology. 2008. PMID: 18418366
-
Antipsychotic efficacy: relationship to optimal D2-receptor occupancy.Eur Psychiatry. 2007 Jul;22(5):267-75. doi: 10.1016/j.eurpsy.2007.02.005. Epub 2007 Apr 6. Eur Psychiatry. 2007. PMID: 17419008 Review.
-
An update on the clinical pharmacokinetics of fexofenadine enantiomers.Expert Opin Drug Metab Toxicol. 2018 Apr;14(4):429-434. doi: 10.1080/17425255.2018.1459565. Epub 2018 Apr 11. Expert Opin Drug Metab Toxicol. 2018. PMID: 29635947 Review.
Cited by
-
A conceptually new treatment approach for relapsed glioblastoma: coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the International Initiative for Accelerated Improvement of Glioblastoma Care.Oncotarget. 2013 Apr;4(4):502-30. doi: 10.18632/oncotarget.969. Oncotarget. 2013. PMID: 23594434 Free PMC article. Review.
-
Cortical Alpha Activity in Schizoaffective Patients.Iran J Psychiatry. 2017 Jan;12(1):1-7. Iran J Psychiatry. 2017. PMID: 28496495 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous